Medicare Advantage Audit Proposal Sent UnitedHealth Down 10%: What Regulatory Gap Risk Looks Like
CMS released its CRUSH anti-fraud proposed rule (CMS-6098-P) on Nov. 16, 2026, including Medicare Advantage RADV audit changes that would extrapolate findings back to payment year 2018 without a fee-for-service adjuster. On Nov. 18, UnitedHealth fell about 10.2%, Humana about 13% and CVS about 5.2%, after UNH had already dropped about 5% the day before. The article explains why a non-final rule can reprice a whole sector that shares one revenue source, how gaps affect stop orders and short puts, and why implied volatility commonly rises after an unresolved shock. It notes the comment period, possible revisions and litigation history, without forecasting the stocks.
Health insurers don't usually trade like meme stocks. This week, a few of them briefly did.
On Wednesday, Nov. 18, 2026, UnitedHealth Group (UNH) fell about 10.2%, the worst performer in the Dow, according to Kiplinger. Humana (HUM) dropped about 13%, and CVS Health (CVS) lost about 5.2%. UNH had already slid about 5% the day before.
No earnings miss. No scandal. The trigger was a proposed rule, a document that isn't even final yet. That makes it a clean real-world example of something every investor and options trader eventually meets: regulatory gap risk, the chance that a government action moves a stock sharply before you have time to react.
What the CMS Medicare Advantage audit proposal (CRUSH) says
On Monday, Nov. 16, the Centers for Medicare & Medicaid Services (CMS) released a broad anti-fraud proposal called CRUSH (Comprehensive Regulations to Uncover Suspicious Healthcare), formally CMS-6098-P. It touches Medicare, Medicaid, CHIP (the Children's Health Insurance Program) and the ACA (Affordable Care Act) marketplaces. The part that hit insurer stocks concerns Medicare Advantage audits.
Some quick background:
- Medicare Advantage (MA) is the private-plan version of Medicare. The government pays insurers like UnitedHealth and Humana to cover seniors.
- Risk adjustment means insurers get paid more for sicker members, based on the diagnoses the plans report.
- RADV (risk adjustment data validation) audits check whether patients' medical records actually support those diagnoses.
According to CMS's fact sheet, the proposal would:
- Extrapolate audit findings starting with payment year 2018. Extrapolation takes the error rate found in a sample of records and applies it to a plan contract's total payments. That's why the potential dollar amounts get large quickly.
- Not apply a "fee-for-service adjuster," an offset insurers have argued should reduce what they owe.
- Let CMS set its own sampling methodology.
CMS estimates the MA audit changes would recover roughly $9 billion per payment year in overpayments.
You may also see a "nearly $90 billion" figure in headlines. That's CMS's estimate of federal savings from the entire CRUSH rule over 2027 through 2036, not from the Medicare Advantage audit piece alone.
Why a "proposed" rule can still move stocks
A proposed rule isn't law. It goes through a public comment period (60 days after Federal Register publication, which puts the deadline around mid-January 2027). CMS can then revise it, and a final version can be challenged in court.
There's real precedent for that last step. In September 2025, a federal court in Texas (Humana Inc. v. Becerra) vacated, or threw out, CMS's 2023 RADV final rule on procedural grounds, according to Milliman. Becker's Payer reports that the new proposal effectively revives provisions from that vacated rule. And Oppenheimer analyst Michael Wiederhorn noted, as quoted by Kiplinger, that CMS "could choose to make adjustments in the final rule."
So why did the market react so hard to something uncertain? Because stock prices reflect expected future cash flows, and markets reprice expectations immediately. A rule that might claw back billions, going back years, changes the range of possible outcomes the moment it's published, not the day it's finalized.
Why the whole sector moved together
UnitedHealth, Humana, CVS (which owns Aetna) and other managed-care companies (insurers that run health plans for government programs and employers) share a major revenue source: Medicare Advantage. A policy change that threatens that stream threatens all of them at once, in different proportions depending on each company's MA exposure.
This is concentration risk at the sector level. Owning several insurers can feel diversified, but if they all answer to the same regulator and depend on the same payment program, one headline can hit every position on the same morning.
It has happened before this year. On Jan. 27, 2026, after CMS proposed a near-flat 0.09% average Medicare Advantage rate increase for 2027, UNH and HUM each fell roughly 19%, according to Axios. The industry had expected an increase of roughly 4% to 6%, Managed Healthcare Executive reported. (Axios noted that UnitedHealth's drop that day also reflected its own weak quarterly revenue and soft 2026 outlook, so not all of that move was the rate proposal.)
What a gap does to an options position
A gap is when a stock opens or trades far from its prior price with little or no trading in between. For options traders, gaps matter in a few specific ways:
- Stop-loss orders don't guarantee your price. A stop order on a stock becomes a market order once triggered. In a gap, it can fill well below the stop level.
- Short options can go deep in the money fast. A put gives its buyer the right to sell shares at a set price (the strike). Someone who sold puts on an insurer, collecting premium (the option's price) on the bet that the stock would stay above the strike, could see those puts move sharply in the money, meaning the stock is now well below the strike, in a single session. Losses on short puts can be large. A cash-secured put seller, who sets aside enough cash to buy the shares, may be assigned (required to buy) shares at a price far above where the stock now trades.
- Long puts gain, but timing matters. Traders who bought puts before the news benefited. Buyers after the news face a different problem, covered next.
Implied volatility after the shock
Implied volatility (IV) is the market's estimate of how much a stock might move, backed out of option prices. Higher IV means more expensive options.
After a sudden, unresolved shock, IV commonly rises, because traders now see a wider range of possible outcomes: a softened final rule, litigation or more downside. In practice, someone buying options after the drop is typically paying a higher premium for the same strike and expiration than they would have days earlier.
If the uncertainty later fades, IV can fall, and option prices can lose value even if the stock barely moves. That's the same "IV crush" dynamic traders see after earnings.
We couldn't find credible published data on UNH or HUM options volume or IV for these specific sessions, so treat this section as an explanation of how options typically behave, not a report on this week's prices. You can check current IV on your broker's option chain.
How companies and the industry responded
According to JournalArta, a CVS spokesperson said the company is "confident in our risk-adjustment program and practices." Humana declined to comment, and UnitedHealth did not comment. The industry trade group AHIP said it is closely reviewing the proposed rule.
Takeaways: regulatory gap risk beyond health insurers
This week's selloff wasn't about a bad quarter. It was the market repricing a policy risk that hits an entire sector through a single regulator and a single revenue stream. A few lessons carry beyond health insurers:
- A proposed rule can move prices as much as a final one, because markets trade on probabilities.
- Companies that depend on the same government program can fall together, which limits how much diversification within that sector helps.
- Gaps can blow through stop orders and turn short-option positions into large losses quickly.
- After a shock, options usually get more expensive, and that extra premium can shrink as uncertainty resolves.
None of this says where these stocks go next. The comment period, any revisions and possible litigation will all take months to play out.
This article is educational commentary on public market events, not personalized investment, trading, or tax advice.
« Back to all insights